Shanghai Junshi Biosciences (HKG:1877) Full Year 2024 Results

Key Financial Results

• Revenue: CN¥1.95b (up 30% from FY 2023).
• Net loss: CN¥1.28b (loss narrowed by 44% from FY 2023).
• CN¥1.30 loss per share (improved from CN¥2.32 loss in FY 2023).

All figures shown in the chart above are for the trailing 12 month (TTM) period

Shanghai Junshi Biosciences Meets Expectations

Revenue was in line with analyst estimates. Earnings per share (EPS) was also in line with analyst expectations.

Looking ahead, revenue is forecast to grow 27% p.a. on average during the next 2 years, compared to a 26% growth forecast for the Biotechs industry in Hong Kong.

Performance of the Hong Kong Biotechs industry.

The company's shares are up 6.1% from a week ago.

Risk Analysis

It's still necessary to consider the ever-present spectre of investment risk. We've identified 1 warning sign with Shanghai Junshi Biosciences, and understanding this should be part of your investment process.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.